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The initiating event in Alzheimer’s disease (AD) is an imbalance in the production and clearance of amyloid beta (Aβ)p e p t i d e s
leading to the formation of neurotoxic brain Aβ assemblies. Cerebrospinal Fluid (CSF), which is a continuum of the brain,
is an obvious source of markers reﬂecting central neuropathologic features of brain diseases. In this review, we provide an
overview and update on our current understanding of the pathobiology of human CSF Aβ peptides. Speciﬁcally, we focused our
attention on the heterogeneity of the CSF Aβ world discussing (1) basic research studies and what has been translated to clinical
practice, (2) monomers and other soluble circulating Aβ assemblies, and (3) communication modes for Aβ peptides and their
microenvironment targets. Finally, we suggest that Aβ peptides as well as other key signals in the central nervous system (CNS),
mainly involved in learning and hence plasticity, may have a double-edged sword action on neuron survival and function.
1.Introduction
The “amyloid cascade hypothesis” suggests that the initiating
event in Alzheimer’s disease (AD) is an imbalance in the pro-
duction and clearance of amyloid beta (Aβ) peptides leading
to the formation of neurotoxic soluble and insoluble brain
Aβ assemblies [1, 2]. Thus, Aβ has become a major thera-
peutic target, with various anti-Aβ strategies being pursued
[3]. Biologically, monomeric Aβ is formed through the en-
zymatic cleavage of the transmembrane amyloid precursor
protein (APP). The discovery of the APP gene was followed
by the identiﬁcation of missense mutations associated with
familial, early-onset AD. These mutations are found in and
around the Aβ region of APP (http://www.molgen.ua.ac.be/
ADmutations/)a n da ﬀect the production or aggregation
properties of Aβ. The physiopathological processing of APP
involves various proteolytic activities leading to a complex
setofAβ fragments.Full-lengthAβ1-40andAβ1-42peptides
are generated by sequential proteolytic processing involving
β and γ-secretases on APP [4]. These peptides (i.e., Aβ1-
40, Aβ1-42) have been the dominant focus of research, but
it is well established that N- and C-terminally truncated
or modiﬁed forms of Aβ peptides also exist in AD brains
[5–9]. The detection of N-terminal truncated Aβ peptides
(especially Aβx-42) in young Down’s syndrome and in pre-
clinical AD brains suggests that the amino-truncated species
are implicated in the very ﬁrst step of amyloidosis [10–
12]. These forms are generated mainly by cleavage of APP
between residues 16 and 17 of the Aβ domain via the α-
secretase and by the alternative β  cleavage of APP triggered
by the β-secretase β-site APP-cleaving enzyme (BACE)1 [13–
15]. Heterogeneity at the C-terminus of Aβ also contributes
to the molecular variety of Aβ peptides; according to some
reports, due to its imprecise cleavage speciﬁcity, γ-secretase
generates Aβ peptides of variable length at the C-terminus
[16]. Recently, γ-secretase has also been shown to cleave near
the cytoplasmic membrane boundary of APP, called ε-site
cleavage [17]. In addition, it has been recently demonstrated2 Journal of Biomedicine and Biotechnology
that the combined activity of α-a n dβ-secretases may
generate the shortest forms (i.e., Aβ 1-15, Aβ 1-16) of C-
terminally truncated Aβ peptides [18]. Body ﬂuids, such as
cerebrospinal ﬂuid (CSF), plasma, serum, or urine represent
a cellular protein-rich information reservoir that contains
traces of what has been secreted into these ﬂuids. In partic-
ular, CSF, which is a continuum of the brain, is an obvious
source of markers reﬂecting central neuropathologic features
of the brain diseases.
This review provides an overview and update on our
currentunderstandingofthepathobiologyofhumanCSFAβ
peptides.
2.CSFAβ PeptidesinTranslationalResearch
Has knowledge on pathobiology of Aβ been somehow trans-
lated to clinical practice? The criteria for the clinical diagno-
sisofADwereestablishedbytheNationalInstituteofNeuro-
logicalandCommunicativeDisordersandStroke(NINCDS)
and the Alzheimer’s Disease and Related Disorders Associ-
ation (ADRDA) workgroup in 1984 [19]. However, in the
intervening 27 years, important advances in our understand-
ing of AD, in our ability to detect the pathophysiological
process of AD, and changes in conceptualization regarding
the clinical spectrum of the disease have occurred [20, 21].
The revised diagnostic criteria proposed in 2011 by the
National Institute of Aging and the Alzheimer’s Association
workgroup include the incorporation of biomarkers of the
underlying disease state and formalization of diﬀerent stages
of disease—“preclinical AD,” “mild cognitive impairment
(MCI) due to AD,” and “AD dementia”—in the diagnostic
criteria [22–24]. Biomarkers are parameters (physiological,
biochemical,anatomic)thatcanbemeasuredinvivoandthat
reﬂect speciﬁc features of disease-related pathophysiological
processes. In recent years, a number of reports have utilised
specific protein/peptide quantitation techniques such as
ELISA to study the levels of selective moieties in CSF as bio-
markers of this neurodegenerative disorder. The three major
alterations in AD brain are extracellular amyloid plaques,
axonal degeneration, and intraneuronal tangles, which can
bemonitoredwiththeCSFbiomarkersAβ1-42,totaltau,and
phosphorylated tau, respectively. The onset and progression
ofADbiomarkerslikelyfollowsanorderedtemporalpattern.
Biomarkers of Aβ amyloid are indicative of initiating or up-
stream events which seem to be most dynamic (i.e., deviate
most signiﬁcantly from normal) before clinical symptoms.
Biomarkers of neuronal injury and neuronal dysfunction
are indicative of downstream pathophysiological processes
which become dynamic later. There is evidence suggesting
that combined assessment of CSF tau and Aβ1-42 have high
diagnostic accuracy for established AD [25]. They may also
be used to identify AD before onset of dementia at the
stage of MCI, as shown in both mono-center and large-scale
heterogeneous multicenter studies [26–30]. Since CSF levels
of the shorter Aβ1-40 isoform are unchanged or increased
in AD, it has been proposed that measurement of the Aβ1-
42/Aβ1-40 ratio might be superior to Aβ1-42 alone [31–
34]. Of note, Aβ1-42 is associated with impairment of
cognitive function from a potentially early to a later disease
phase [35–37]. Decreased CSF Aβ1-42 is also seen in other
neurodegenerative disorders [38].Recentstudieshaveshown
associations between shorter forms of Aβ peptides and
speciﬁc dementias: decreased Aβ1-38 levels correlated with
frontotemporal dementia [39]a n dA β1-37 with Lewy Body
dementia [40]. Thus, the detection of the whole spectrum of
Aβ peptides in the CSF could be useful in order to improve
early diﬀerential diagnosis.
3. The LargeFamily of CSF Aβ Peptides:
The MassSpectrometry-BasedDetection
The predominant protein component of amyloid plaques are
strongly aggregating peptides with an approximate molecu-
lar mass of 4kDa. The main plaques component is the 42
aminoacidisoformofAβ;thisisoformishighlyhydrophobic
and forms oligomers and ﬁbrils that accumulate in extracel-
lularplaques[41].Thedepositionofthepeptideinplaquesis
considered the underlying basis for the decrease in CSF Aβ1-
42 levels seen in AD and incorporated in the new diagnostic
criteria. In addition, other isoforms of Aβ,f o re x a m p l e ,
pyro Aβ3-42, Aβ4-42, pyro Aβ11-42, Aβ17-42, Aβ1-40, and
Aβ11-40havebeendetectedinthebrainsofsporadicADand
familialADcases[5–12,42–46].Aβ peptidesheterogeneityis
observed also in the human CSF (see Table 1)[ 47–58]. The
proteolytically processed Aβ peptides, however, are diﬃcult
to detect in the CSF-using standard methods, possibly be-
cause they comprise a heterogeneous set of both N- and
C-terminally truncated peptides, some of which are present
only at low levels. Many investigators used mass spectrom-
etry (MS) for studying human CSF Aβ peptides. MS allows
for the detection of a variety of modiﬁed and truncated Aβ
peptides,thusenablingamoredetailedandunbiasedanalysis
of fragments that may play a role in neurodegeneration.
T h et w om a i na p p r o a c h e sa r e( 1 )t h eu s eo fp r e a c t i v a t e d
chip arrays that allow coupling with speciﬁc antibodies com-
bined with surface-enhanced laser desorption and ionization
time-of-ﬂight (SELDI-TOF) MS (2) immunoprecipitation
combined with matrix-assisted laser desorption/ionization
time-of-ﬂight (MALDI-TOF) MS. An immunoproteomic
approach—which combines speciﬁcity of 6E10 (against Aβ
epitope1-16)mAbcapturewithprecisionofspectralanalysis
(i.e., SELDI-TOF MS)—has recently been successfully used
to analyze Aβ peptides in human CSF; Maddalena et al.
[50] detected 9 C-terminally and 1 N-terminally truncated
Aβ peptides in CSF of AD patients and healthy controls
subjects. while, with an analogous protocol, 10 Aβ fragments
were found by Lewczuk et al. [55, 58]. Immunoprecipitation
experiments employing 4G8 mAb and MALDI-MS analyses
of Aβ peptides from 1mL CSF revealed the presence of two
previously unidentiﬁed N-terminally truncated Aβ peptides
(i.e., Aβ11-30, Aβ11-40), along with a number of C-ter-
minally truncated forms [47, 48]. Since 6E10 and 4G8 mAbs
bind diﬀerent portions of Aβ sequence, we tested whether
the combined use of these two mAbs could improve the
capture of N and C-terminally truncated Aβ peptides; of
note, applying this optimized immunoproteomic assay—
that employs very low sample volume (5μLo fC S Ff o re a c hJournal of Biomedicine and Biotechnology 3
Table 1: Summary of Aβ peptides in human CSF.
Aβ Peptides Theoretical mass∗ (Da) Literature
Aβ1-12 1424.61 [47]
Aβ1-13 1561.67 [47–49]
Aβ2-14 1583.70 [50]
Aβ1-14 1698.73 [47–49]
Aβ1-15 1826.78 [47–49]
Aβ3-17 1881.90 [48]
Aβ2-17 1952.94 [48]
Aβ1-16 1954.88 [47–49]
Aβ1-17 2067.96 [47–52]
Aβ1-18 2167.03 [47–51]
Aβ11-30 2212.11 [47]
Aβ1-19 2314.10 [47–49, 51, 52]
Aβ1-20 2461.17 [47–49]
Aβ6-27 2521.16 [53]
Aβ11-34 2608.39 [53]
Aβ1-27 3133.44 [53]
Aβ11-40 3150.68 [47, 51, 54]
Aβ6-34 3167.60 [53]
Aβ1-28 3261.53 [47, 48, 53, 55]
Aβ6-35 3298.63 [53]
Aβ12-43 3306.80 [53]
Aβ10-40 3313.74 [51, 54]
Aβ1-29 3318.56 [55]
Aβ11-42 3334.80 [51, 54, 56]
Aβ1-30 3389.59 [47–49, 53]
Aβ11-43 3435.85 [53]
Aβ3-34 3599.80 [53]
Aβ1-33 3672.78 [47, 49–51, 54, 55, 57]
Aβ1-34 3785.87 [47, 49–51, 53–55, 57]
Aβ1-35 3916.91 [51, 53, 57]
Aβ1-36 4015.98 [51]
Aβ1-37 4073.00 [47, 49–51, 54, 55, 57, 58]
Aβ1-38 4130.02 [47, 49–51, 53–55, 57, 58]
Aβ1-39 4229.09 [47, 49–51, 54, 55, 57, 58]
Aβ1-40 4328.16 [47, 49–51, 53–55, 57, 58]
Aβ1-42 4512.28 [47, 49–51, 54–58]
Aβ3-44 4526.33 [58]
Aβ1-45 or Aβ2-46 4825.48 or 4809.52 [55]
Aβ3-47 4851.56 [58]
∗The masses presented are the monoisotopic protonated molecules.
spot)—wedetectedatotalof15Aβpeptides(12C-terminally
and 3 N-terminally truncated forms) in human CSF [51].
In addition, we determined mass proﬁles of Aβ peptides
in the CSF of patients carrying familial AD-associated muta-
tions (i.e., APP T719P, PS1 P117L, and PS2 T122R); these
mutations were associated with an overall reduction of Aβ
species. Interestingly, the APP T719P mutation unbalanced
the relative proportion of Aβ peptides with a reduction of
Aβ1-40 and Aβ1-42 paralleled by an increase of Aβ1-38 and
Aβ10-40 [54]. In accordance with these data, Portelius and
coauthors [49] reported a reduction C-terminally truncated
Aβ peptides in CSF of aﬀected and unaﬀected subjects
carrying PS1 A431E mutation. An unbalance of Aβ isoforms
was also detected in CSF of sporadic AD and MCI patients
[50, 52, 56, 57]. Interestingly, within a phase II clinical trial,
it has been recently demonstrated that Aβ1-14, Aβ1-15, and
Aβ1-16 are positive and very sensitive biomarkers for γ-
secretase inhibition (even at doses that do not aﬀect Aβ1-42
orAβ1-40)[59].Thus,Aβ isoformsmaybenovelbiomarkers
to monitor the onset and progression of cognitive decline
and the biochemical eﬀect of disease-modifying drugs in AD
clinical trials.
4.Beyond Aβ Monomers: CSFCirculating
Aβ Oligomers
In the human brain it is likely that multiple Aβ assemblies,
that are in dynamic equilibrium almost simultaneously, alter
b r a i nc e l lf u n c t i o na n dt h a td i ﬀerent toxic eﬀects may occur
virtually concurrently in various regions of the cerebrum.
Several lines of evidence have converged to demonstrate that
soluble oligomers of Aβ may be responsible for synaptic
dysfunction in AD animal models and in the brains of AD
patients [46,60,61].Smalldiﬀusible Aβ o li g o me r sha v ebee n
shown to exert neurotoxic eﬀects in cultured neurons [62–
64].Ithasbeenhypothesizedthatsuchpreﬁbrillarassemblies
might also be neurotoxic in vivo since synaptic, electrophysi-
ological, and behavioral changes have been well documented
in young APP transgenic mice before plaque formation
[65, 66]. Accordingly, soluble Aβ oligomers have been
found to block, in vivo, hippocampal long-term potentiation
(LTP), a synaptic correlate of memory and learning [67–
71]. Importantly, Aβ immunotherapy can protect against
the neuropathology and cognitive deﬁcits observed in APP
transgenic mice and also prevent the LTP inhibition induced
by Aβ oligomers[68].SolubleoligomericAβ hasbeenshown
to be present in human CSF [72–74]. Human derived soluble
Aβ seems to have a pathophysiological role in the brain; the
CSF-derived Aβ dimers—and not the monomers—potently
disrupt synaptic plasticity in vivo [75]. Of note, it has
been reported that CSF circulating oligomers are increased
in AD and MCI patients, and their levels are negatively
correlated with Mini-Mental State Examination scores [76,
77]. Thus, an emerging strategy within the AD ﬁeld is to use
oligomeric Aβ as a possible biomarker/therapeutic target for
the disease. The actual identity of the oligomer participating
in AD pathogenesis remains elusive although several lines of
evidence suggest that AD-associated oligomers are primarily
composed of Aβ42. Nevertheless Gao and coworkers, using a
novelmisfoldedproteinassay,foundanenrichmentofAβ40-
containing oligomers in AD CSF [78] and suggested these
assemblies as biomarker for early diagnosis of AD. Although
Aβ oligomersareattractiveADbiomarkercandidates,several
issues relating to these molecules persist. The levels of these
Aβ species in CSF seem to be very low in comparison
with Aβ monomers and the precise molecular identity of
these soluble toxins remains unsettled; thus more precise
mass spectrometry analyses are needed in order to better4 Journal of Biomedicine and Biotechnology
characterize the molecular weight and composition of the
most neurotoxic species. Furthermore, assays suitable for
large clinical studies are still to be developed for these mole-
cules. The development of conformation-sensitive antibody
domains targeting the Aβ oligomers [79–83]i so fg r e a t
interest for research in this ﬁeld. Targeting the pathological
assemblies of Aβ with speciﬁc probes, for mechanistic stud-
ies, for intracellular imaging, or for therapeutic purposes, is
therefore very important.
5. Aβ Peptides AreDouble-Edged Sword
SignalsTransmittedBothviaVolumeand
WiringTransmission
As discussed above, Aβ peptides have been regarded as the
principal toxic factor in the neurodegeneration of AD. In-
tense research eﬀort has, therefore, been directed at deter-
mining their sources, activities, and fates, primarily with a
view of preventing their formation or toxic actions, or pro-
moting their degradation.
These are important studies and very promising ones for
a better understanding of the pathogenesis of AD. However,
in our opinion, a crucial aspect is the discovery of the physi-
ological role of these peptides.
Thus, the following points will be brieﬂy discussed as far
as the Aβ peptides are concerned:
(a) communication modes for these peptides, hence
(volumetransmission(VT))versus(wiringtransmis-
sion (WT)) versus (VT and WT);
(b) micro-environmentwherethetargetsforAβ peptides
are located, hence plasma membrane versus intracel-
lular environment;
(c) possible physiological roles of Aβ peptides.
Finally, a previously published theoretical proposal [84]
will be summarised since it can give a possible frame for
interpreting otherwise contradictory data on Aβ peptides
functions. The hypothesis is based on the concept that Aβ
peptides as well as other key signals in the central nervous
system(CNS)mainlyinvolvedinlearning,andhenceplastic-
itymayhaveadouble-edgedswordactiononneuronsurvival
and function.
5.1. Communication Modes for Aβ Peptides and Their Mi-
croenvironment Targets. It has been proposed that two main
modes for intercellular communication are in operation in
the CNS, namely, the VT and the WT [85].
The characteristics of the channel connecting two nodes
of the network, that is, the cell source of the signal with the
cell-target of the signal allow distinguishing the VT from the
WT.
(i)VTischaracterizedbyachannelwithapoorly deﬁned
physical substrate and signal transmission takes place via
diffusion (or vector migration) in the medium interposed
between nodes. Recently, it has been shown that several
messages can be sent via microvesicles (acting as protective
containers hence like the bag of a roamer), dispatched into
the extracellular space (ECS) and diﬀusing until the proper
targets are reached [86–88].
Diﬀerent types of microvesicles have been described,
which are the result of speciﬁc cellular phenomena [86]. In
particular, exosomes are microvesicles contained within a
special class of membrane-bound organelles (endosomes),
which can be released by fusion of the limiting membrane
of the MVB with the plasma membrane.
(ii) WT is characterized by the transmission of the signal
alongachannelwithawell-deﬁnedphysicalsubstrate;thus,a
“wire” links the source node with the target node. Classically,
in the case of neural networks, the WT-channel is formed by
an axon and a chemical synapse.
However, two more subclasses of WT play a role in the
CNS. The ﬁrst one is represented by the well-characterized
gap junctions, while the second one, the clear-cut in vivo
demonstration of which has not yet been provided, is repre-
sented by the tunnelling nanotubes (TNTs) that are transient
structures forming a “private” direct channel connecting two
cells. They have a diameter of 50–200nm and a length up to
several cell diameters. Several in vitro studies demonstrated
that these structures make possible the exchange of proteins,
mtDNA, RNA, and whole organelles between cells [89]. It
is interesting to note that Aβ peptides can be transmitted
according to both VT and WT. Actually, it has been shown
that these signals can use several possible modes of intercel-
lular communication:
(i) the classical VT mode that is diﬀusion in the ECS
[90–94],
(ii) the Roamer Type of VT that is diﬀusion via exosomes
[95–99],
(iii) the TNT mode of WT [100].
The targets for the Aβ peptides are located both at the
plasma membrane level [101, 102] and at intracellular level
where they may exert an “intracrine function” [95, 103,
104].
5.2. Possible Functional Roles of Aβ Peptides. We completely
agree with Pearson and Peers’ view that Aβ peptides should
have important physiological roles and may even be crucial
for neuronal cell survival and CNS function. Thus, the view
of Aβ being a purely toxic peptide requires a reevaluation
[105]. In support of such a proposal, there are several papers,
twoofthesewillbecitedsincewhiletheﬁrstoneshowsarole
of Aβ peptides on learning [106], the other one opens a new
ﬁeld by giving evidence for a possible role of these peptides
as antimicrobial agents [107].
Thus, it has been shown that, in contrast with its path-
ological role when accumulated, endogenous Aβ in normal
hippocampimediateslearningandmemoryformationprob-
ably via nicotinic acetylcholine receptors. Furthermore, hip-
pocampal injection of picomolar concentrations of exoge-
nous Aβ1-42 enhances memory consolidation. Hence, Aβ
peptides, including Aβ1-42, play an important physiological
role in hippocampal memory formation.Journal of Biomedicine and Biotechnology 5
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Figure 1: Schematic representation of the “Push and Pull Control” of structural and functional plasticity of neuronal circuits and how this
control is related to learning processes (plastic changes of the circuits) and maintenance of the memory traces (stability of the circuits). The
possible actions of Aβ peptides as double-edged sword signals are indicated. Broken arrows indicate reduction or inhibition.
As mentioned above, recently a new possible function for
Aβ peptides has been demonstrated, namely, the antimicro-
bial action. Thus, it has been shown that many of the phys-
iochemical and biological properties previously reported
for Aβ are similar to those of a group of biomolecules
collectively known as “antimicrobial peptides” (AMPs; also
called “host defense peptides”) which function in the innate
immune system. These peptides are potent, broad-spectrum
antibiotics that target several infective agents. In particular,
thepleiotropicLL-37peptideisawidelyexpressedarchetypal
AMP present also in humans that exhibits striking similari-
ties to Aβ, including a propensity to form cytotoxic soluble
oligomers and insoluble ﬁbrils with classical histochemical
properties of tinctorial amyloid. Soscia et al. [107] ﬁndings
revealthatAβexertsantimicrobialactivityagainsteightcom-
mon and clinically relevant microorganisms with a potency
equivalent to, and in some cases greater than, LL-37. These
ﬁndings obviously impose a great caution in developing
futureADtreatmentstrategiesbasedonthedrasticreduction
of synthesis and levels of Aβ peptides.
5.3. Double-Edged Sword Action of Aβ Peptides on Neuron
Plasticity and Survival. More than one century ago, Tanzi
proposedthatlearningprocessesintheCNSarebasicallydue
to plastic changes of neuronal networks [108].
As pointed out by Taylor and Gaze, neuronal plasticity
allowing continuous CNS adaptation to the challenges of the
environment plays a fundamental role not only for learning
processes. Actually, plasticity in the nervous system means
a patterned or ordered alteration in structure and function
brought about by development, experience, or injury [109].
Thus, this deﬁnition mentions age, learning, and lesions
as factors triggering out plasticity.
In this paper the concept is introduced that physiological
processes(suchaslearningandmemory)aswellasrepairable
processes (such as those occurring after lesions or during
ageing), being all rooted in CNS rearrangements, are com-
peting for the brain plasticity [110], which exists as a ﬁxed
amount (“total brain plasticity capability,” see [84]).
It has been demonstrated that some signals, such as ex-
cito-amino acids, Aβ peptides, and α-synuclein (α-syn), are
not only involved in information handling by the neuronal
circuits, but also trigger out CNS plasticity [84]. It has also
been shown that these signals are potentially dangerous pos-
sibly since, interalia, they force the neuronal circuits to move
from one stable state towards a new state. Several mecha-
nismsareputinactiontoprotectneuronsandglialcellsfrom
these potentially harmful signals and hence favouring the
emergence of only their physiological functions. However,
ageing and neurodegenerative diseases, on one side, increase
the need of plasticity for the CNS repair but, on the other
side, cause a reduction in the secretion of several trophic
factors (e.g., BDNF and NGF) leading to a less eﬀective neu-
roprotection and deﬁcits in neural plasticity [111, 112].
Againstthisbackground,ithasbeenshownthatinageing
and neurodegenerative diseases functionally ambivalent (i.e.,
double-edged sword) signals such as Aβ and α-syn are se-
creted at a high rate possibly in the attempt of maximizing
neuronal plasticity. It has been proposed that in the long
run these peptides do not exert their possible physiological
actions but on the contrary may favour neurodegenerative
processes.6 Journal of Biomedicine and Biotechnology
Soscia et al. [107] have demonstrated that an increased
Aβ generation/accumulation leading to AD pathology may
be mediated by a response of the innate immune system to
a perceived infection. This model is in agreement with data
supporting a central role for neuroinﬂammation in AD neu-
ropathology [113].
T h u s ,n o to n l yg e n e t i cf a c t o r sm a yc o n t r i b u t et oa c t i v a -
tion of the innate immune system by regulating Aβ produc-
tion and clearance but also a transient infection may lead to
a self-perpetuating innate immune response.
These ﬁndings allow an update of the hypothesis made in
the JNT 2009 [84] (see Figure 1).
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